Copper-based imaging agent awarded FDA’s Breakthrough designation

An investigational copper-64 radiopharmaceutical designed to improve the detection of recurrent prostate cancer has received Breakthrough Therapy designation from the U.S. Food and Drug Administration. 

This development comes after clinical trials have signaled that it may identify more disease sites than currently used PSMA PET imaging agents. Developed by Clarity Pharmaceuticals, 64Cu-SAR-bisPSMA is a PET imaging agent that pinpoints prostate-specific membrane antigen. The radiopharmaceutical combines two PSMA-targeting molecules with the company’s proprietary sarcophagine technology, a cage-like chelator designed to securely hold copper isotopes and prevent their release into the body. 

The agent uses copper-64, which has a half-life of about 13 hours, compared with the shorter half-lives of commonly used gallium-68 and fluorine-18 PET tracers. This allows imaging at later time points, including about 24 hours after injection, potentially improving tumor-to-background contrast and lesion detection. The longer half-life also could be beneficial in expanding access to prostate cancer diagnostics. 

The FDA’s designation is backed by clinical evidence from the Phase 2 Co-PSMA trial, which compared 64Cu-SAR-bisPSMA with gallium-68 PSMA-11 in 50 men with biochemical recurrence following prostatectomy. Next-day imaging with 64Cu-SAR-bisPSMA-detected PSMA-positive lesions in 78% of participants, compared to 36% with gallium-68 PSMA-11. The study also found that imaging results prompted planned management changes in 44% of participants, including transitions from observation to active treatment and adjustments to radiation treatment fields. 

Subscribe to Radiology Business News

Additional findings came from the Phase 1/2a COBRA trial, which enrolled 52 patients with biochemical recurrence and negative or equivocal findings on standard imaging. Among those patients, next-day imaging with the agent produced positive scans in 58% to 80% of participants, depending on the reader, compared with 44% to 58% with same-day imaging. In a subset of 20 patients who underwent subsequent standard-of-care PSMA PET, the agent identified more lesions and positive scans. Investigators of that study reported that the additional findings could lead to treatment changes in approximately half of patients. 

"Receiving this Breakthrough Therapy designation is one of the most significant milestones in our prostate cancer program to date. ,” Alan Taylor, PhD, executive chairperson of Clarity Pharmaceuticals, said in a news release. “Its importance is further amplified given fewer than half of designation requests across all therapeutic areas are successful.” 

The FDA's Breakthrough Therapy designation is intended to expedite the development and review of investigational products for serious conditions when preliminary clinical evidence suggests substantial improvement over available options on a clinically significant endpoint. It provides access to more intensive FDA guidance and senior-level involvement during development and review. 

Read more here. 

Hannah Murphy
Hannah Murphy, Editor

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.

Subscribe to Radiology Business News

Subscribe to Radiology Business News